文献速递基础与转化研究新药、器械与细胞基因治疗研发

工程化锌指抑制因子在非人灵长类伤害感受器中实现SCN9A持久选择性抑制

Engineered zinc finger repressors induce a prolonged and selective repression of SCN9A in nociceptors of nonhuman primates.
PubMed 文献 · Sci Transl Med · 2026-03-25

该研究开发靶向人/非人灵长类SCN9A基因的工程化锌指抑制因子(ZFR),通过AAV递送在iPSC来源神经元中降低SCN9A且未检出脱靶活性。小鼠SNI神经痛模型中AAV-ZFR使DRG的Scn9a抑制≤70%并减轻痛觉过敏;非人灵长类经AAV9鞘内腰椎注射后1个月DRG组织及伤害感受器单细胞水平SCN9A受抑。领先产品ST-503在6个月NHP研究中使DRG组织SCN9A抑制50%,未见剂量限制性毒性或神经、心脏安全药理学影响。

要点

  • AAV9-ZFR经鞘内腰椎递送可在NHP伤害感受器中选择性抑制SCN9A。
  • 小鼠SNI模型中Scn9a抑制≤70%与痛觉过敏减轻相关。
  • ST-503在6个月NHP研究中DRG组织SCN9A抑制50%,未见剂量限制性毒性。

核心结论

  • AAV递送的ZFR靶向SCN9A可在非人灵长类中实现持久且选择性的 repression,支持其作为周围神经病潜在疗法的进一步开发。

研究设计与样本

  • 临床前研究:在人iPSC来源神经元、小鼠SNI神经痛模型及非人灵长类中评估AAV-ZFR;NHP 6个月研究评估领先产品ST-503。

主要发现

  • 人iPSC来源神经元中AAV-ZFR降低SCN9A且未检出脱靶活性。
  • 小鼠SNI模型中AAV-ZFR使DRG的Scn9a抑制≤70%,并减轻痛觉过敏。
  • NHP经AAV9鞘内腰椎递送后1个月,DRG组织及伤害感受器单细胞水平SCN9A受抑。
  • ST-503经鞘内腰椎输注6个月使DRG组织SCN9A抑制50%,未见剂量限制性毒性或神经、心脏安全药理学影响。

临床怎么用

  • 目前为临床前证据,尚不能直接用于临床决策;提示AAV-ZFR靶向SCN9A可能成为周围神经病镇痛新策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Peripheral neuropathies are estimated to affect several million patients in the US, with no long-lasting therapy currently available. In humans, the Nav1.7 sodium channel, encoded by the SCN9A gene, is involved in a spectrum of inherited neuropathies and has emerged as a promising target for analgesic drug development. The development of a selective Nav1.7 inhibitor has been challenging, in part because of structural similarities with other Nav channels. Here, we present preclinical studies for a genomic medicine approach using engineered zinc finger repressors (ZFRs) specifically targeting the human/nonhuman primate (NHP) SCN9A gene. Adeno-associated virus (AAV)-mediated delivery of ZFRs in human induced pluripotent stem cell (iPSC)-derived neurons resulted in the reduction of SCN9A with no detectable off-target activity. In the spared nerve injury (SNI) neuropathic pain mouse model, AAV-ZFR administration resulted in ≤70% repression of Scn9a in mouse dorsal root ganglia (DRGs) and was associated with reduction in pain hypersensitivity. AAV9-mediated intrathecal-lumbar (IT-lumbar) delivery of ZFRs in NHPs demonstrated repression of SCN9A in bulk DRG tissue and single-cell levels in nociceptors 1 month after treatment. A lead AAV9-ZFR investigational product, ST-503, was developed and further evaluated in a 6-month study in NHPs. ST-503 administration by IT-lumbar infusion resulted in 50% repression of SCN9A in bulk DRG tissue at 6 months without findings of dose-limiting toxicity or impact on neurological and cardiac safety pharmacology. Together, our results support further development of an AAV-delivered ZFR as a potential therapy for patients with peripheral neuropathies.

来源:Sci Transl Med,查看原文。版权归原作者所有。

引用

  1. Samie M, Parman T, Jalan M, et al. Engineered zinc finger repressors induce a prolonged and selective repression of SCN9A in nociceptors of nonhuman primates. Sci Transl Med. 2026. PMID: 41880518. doi:10.1126/scitranslmed.adu0217

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。